|
| RESEARCH LETTER |
|
|
|
| Year : 2006 | Volume
: 38
| Issue : 5 | Page : 357-358 |
| |
The effect of rabeprazole and its isomers on aspirin and histamine-induced ulcers in rats
SL Bodhankar, BB Jain, BP Ahire, RB Daude, PP Shitole
Department of Pharmacology, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Erandwane, Pune-411038, Maharashtra, India
Correspondence Address:
S L Bodhankar
Department of Pharmacology, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Erandwane, Pune-411038, Maharashtra
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.27706
How to cite this article:
Bodhankar S L, Jain B B, Ahire B P, Daude R B, Shitole P P. The effect of rabeprazole and its isomers on aspirin and histamine-induced ulcers in rats. Indian J Pharmacol 2006;38:357-8 |
How to cite this URL:
Bodhankar S L, Jain B B, Ahire B P, Daude R B, Shitole P P. The effect of rabeprazole and its isomers on aspirin and histamine-induced ulcers in rats. Indian J Pharmacol [serial online] 2006 [cited 2023 Mar 29];38:357-8. Available from: https://www.ijp-online.com/text.asp?2006/38/5/357/27706 |
All currently available proton pump inhibitors (PPI) are substituted benzimidazole pro-drugs and chiral compounds. Rabeprazole is an inhibitor of the gastric proton pump. It causes dose-dependent inhibition of acid secretion and has a more rapid onset of action than omeprazole.[1] Rabeprazole is mainly reduced via the non-enzymatic pathway to rabeprazole-thioether. Therefore, the acid inhibitory effects of rabeprazole are less influenced by CYP2C19 genotype status[2] and therefore, may be preferred in a population with a high incidence of CYP2C19 poor metaboliser status. Among the PPIs, omeprazole, lansoprazole, pantoprazole and rabeprazole are marketed as racemic mixtures of R- and S-enantiomers.[3] S-enantiomers of omeprazole and pantoprazole are also marketed separately. Rabeprazole is available as a racemic mixture of two isomers - R (+)- isomer (Dexrabeprazole) and S (-)- isomer in 1:1 proportion.[4]
The objective of the present study was to investigate the anti-ulcer activity of R (+)- and S(-)-rabeprazole in aspirin- and histamine-induced ulcers in rats. Samples of racemate, R- and S-isomers of rabeprazole, aspirin and histamine were supplied by Emcure Pharmaceuticals Ltd., Pune, India. The doses of racemate, R- and S-isomers of rabeprazole were 1.25, 2.5, 5 and 10 mg/kg body weight, respectively. Rabeprazole and its isomers were dissolved in normal saline (0.9%). Aspirin (900 mg/kg, p.o.) and histamine (7.5 mg/kg, i.p.) were used for ulcer induction.[7], [8] Aspirin was suspended in sodium carboxy methyl cellulose (0.5% w/v) and histamine was dissolved in distilled water. Control animals were injected with normal saline.
Wistar albino rats of either sex (180±10 g) were purchased from the National Toxicology Centre, Pune and Yash Farms, Pune. The animals were housed in polypropylene cages at 25 + 1°C and relative humidity of 45-55% in a clean environment under 12:12 light:dark cycle. The animals had free access to food pellets (Chakan Oil Mill, Pune, India) and were provided filtered water ad libitum , during housing. The experimental protocol was approved by the Institutional Animal Ethics Committee (IAEC) of the Poona College of Pharmacy.
In the aspirin-induced ulcer model, the animals were deprived of food for 36 hours before the experiment. Each group, consisting of 6 animals of either sex, having mean body weight of 180±10 g received aspirin (900 mg/kg, body weight orally), 60 min after the intraperitoneal administration of the test drug or vehicle (control). The rats were sacrificed 6 h later and their stomachs were excised and fixed with 1% formalin. Every opened and spread-out stomach was photographed at X7 magnification and the ulcer area was measured by superimposing graph paper with minimum square equal to 1 mm 2.
In the histamine-induced ulcer model, the selection of the animals and the housing conditions were the same as described above. The animals were grouped as 6 rats per group, with a total of 5 groups, and marked for identification before the commencement of the experiment. The animals were deprived of food for 24 hours before the commencement of the experiment. Each group received histamine (7.5 mg/kg, body weight, i.p.), 30 min after the intraperitoneal administration of the test drug or vehicle (control). The rats were sacrificed 4 h later, Their stomachs were excised and fixed with 1% formalin. Every opened and spread-out stomach was analysed as described above.
The results are expressed as mean±SD and presented in [Table - 1]. A comparison between the groups was made using the one-way analysis of variance (ANOVA), followed by Dunnett's test.
Aspirin (900 mg/kg) produced punctate lesions on the glandular portion of the rat stomach with mean±SD area of 5.07±1.70 mm 2. Both isomers of rabeprazole dose- dependently reduced the number of ulcers and mean ulcer areas as shown in [Table - 1].
R(+)-rabeprazole (10 mg/kg) was more effective than S(-)-rabeprazole (10 mg/kg) and racemate rabeprazole (10 mg/kg). Histamine (7.5 mg/kg) produced ulcers in rats with mean±SD area of 10.31±2.52 mm 2. Histamine-induced ulcers were inhibited dose-dependently by racemate rabeprazole and isomers as shown in [Table - 1]. R (+)-rabeprazole (10 mg/kg) was more effective than S (-)-rabeprazole (10 mg/kg) and equally effective as racemate rabeprazole (10 mg/kg).
The analysis of data shows that using equal doses, in the aspirin-induced ulcer model, the ratio (R-isomer % inhibition ulcer area):(racemate % inhibition ulcer area) is 1.93 + 0.9 , while in the histamine-induced ulcer model, the ratio is 1.1 + 0.09. This shows that in its cytoprotective action, the R-isomer showed almost twice the ulcer protective effect as produced by racemate, at equivalent doses.
Using half-dose of R-isomer compared to racemate, in the aspirin-induced ulcer model, the ratio (R-isomer % inhibition ulcer area):( racemate % inhibition ulcer area) is 1.34 + 0.19, while, in the histamine-induced ulcer model, the ratio is 0.94 + 0.04. Hence, approximately 50% of the dose of R-isomer is adequate to obtain equal antiulcer response with the racemate.
The corresponding values for the S-isomer are as follows. Using equal doses, in the aspirin-induced ulcer model, the ratio (S-isomer % inhibition ulcer area):(racemate % inhibition ulcer area) is 1.04 + 0.2, while, in the histamine-induced ulcer model, the ratio is 0.43 + 0.5. Using half-dose of S-isomer compared to racemate, in the aspirin-induced ulcer model, the ratio (S-isomer % inhibition ulcer area):(racemate % inhibition ulcer area) is 0.70 + 0.06 (mean + SD), while, in the histamine-induced ulcer model, the ratio is 0.26 + 0.38. Ratios of less than 0.9 indicate that the S-isomer is less effective than the R-isomer.
The critical factors in maintaining the defense and integrity of the gastric and intestinal wall, mediated by prostaglandins, are mucosal blood flow, mucus and bicarbonate secretion, epithelial proliferation and repair.[5] Aspirin induces gastric lesions through blocking prostaglandin production.[6] Rabeprazole was reported to significantly increase the production of mucin (a defense factor) in rats. It prevented or reduced the size of gastric ulcers caused by water immersion in rats. It also prevented stress-induced increase in gastric mucosal peptide-leukotrine content with differing mucosal prostaglandin levels.[7] In the present study, rabeprazole caused dose-dependent inhibition of aspirin-induced ulceration. R(+)-rabeprazole appears to be the major isomer having anti-ulcer activity. The induction of experimental gastric ulcers by histamine administration has long been recognised and is mediated through enhanced gastric acid secretion and vasospastic action of histamine. The model of histamine-induced ulcer in Guinea pigs has been described earlier.[8] In the present study, rats were used. Histamine-induced gastric ulcers were inhibited by racemate rabeprazole and its isomers. R-rabeprazole was found to be more effective than the racemate and S-rabeprazole.
In the present study, we provide the evidence that R (+)-rabeprazole (Dexrabeprazole) is more effective than S (-)-rabeprazole and the racemate in inhibiting acid related gastric lesions in rats.
| Acknowledgments | |  |
The author would like to thank Dr. S.S. Kadam, Principal and Dr. K.R. Mahadik, Vice-Principal, BVDU'S Poona College of Pharmacy for their keen interest and Emcure Pharmaceuticals, Pune for financial support.
| References | | |
| 1. | Langtry HD, Markham A. Rabeprazole: A review of its use in acid-related gastrointestinal disorders. Drugs 1999;58:725-42.  [PUBMED] |
| 2. | Miura M, Kagaya H, Tada H, Sagae Y, Satoh S, Habuchi T, et al . Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipient who are CYP2C19 extensive metabolizers. Xenobiotica 2005;35:479-86. |
| 3. | Welage LS. Pharmacologic features of proton pump inhibitors and their potential relevance to clinical practice. Gastroenterol Clin North Am 2003;32:25-35. [PUBMED] |
| 4. | Takakuwa S, Chiku S, Nakata H, Yuzuriha T, Mano N, Asakawa N. Enantioselective high-performance liquid chromatographic assay for determination of enantiomers of a new anti-ulcer agent, E3810, in beagle dog plasma and rat plasma. J Chromatogr B Appl 1995;673:113-22. [PUBMED] |
| 5. | Wallace JL, Tigley AW. Review article: New insights into prostaglandins and mucosal defence. Aliment Pharmacol Ther 1995;9:227-35. [PUBMED] |
| 6. | Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-5. [PUBMED] |
| 7. | Cao H, Wang M, Jia J, Wang Q, Cheng M. Comparison of the effects of pantoprazole enantiomers on gastric mucosal lesions and gastric epithelial cells in rats. Health Sci 2004;50:1-8. |
| 8. | Cao H, Wang MW, Sun L, Inkejima T, Hu ZQ, Zhao WH. Pharmacodynamic comparison of pantoprazole enantiomers: inhibition of acid-related lesions and acid secretion in rats and guinea-pigs. Pharm Pharmacol 2005;57: 923-7. |
Tables
[Table - 1]
| This article has been cited by | | 1 |
Formulation development and pharmacokinetic evaluation of enteric-coated dexrabeprazole tablets |
|
| Tae Jin Lee, Dohyun Kim, Jae Cheon Kim, Si Won Ro, Dong Hee Na | | Journal of Pharmaceutical Investigation. 2022; | | [Pubmed] | [DOI] | | | 2 |
GASTROPROTECTIVE AND ULCER HEALING ACTIVITY OF ETHANOLIC EXTRACT OF ADIANTUM LUNULATUM |
|
| M. N Deshpande, N Balekar | | INDIAN DRUGS. 2019; 56(03): 68 | | [Pubmed] | [DOI] | | | 3 |
Development and Validation of Rapid, Sensitive Rp-Uplc Method for Determination of Related Impurities in Dexrabeprazole Sodium |
|
| Santosh T. Khadangale, Vitthal M. Dhalape, Rahul V. Pinjari | | Oriental Journal of Chemistry. 2018; 34(5): 2425 | | [Pubmed] | [DOI] | | | 4 |
Antioxidant and anti-inflammatory activities contribute to the prophylactic effect of semi-purified fractions obtained from the crude methanol extract of Muntingia calabura leaves against gastric ulceration in rats |
|
| Tavamani Balan,Mohd. Hijaz Mohd Sani,Salahuddin Haji Mumtaz Ahmad,Velan Suppaiah,Norhafizah Mohtarrudin,Zainul Amiruddin Zakaria | | Journal of Ethnopharmacology. 2015; 164: 1 | | [Pubmed] | [DOI] | | | 5 |
Normal and polar-organic-phase high-performance liquid chromatographic enantioresolution of omeprazole, rabeprazole, lansoprazole and pantoprazole using monochloro-methylated cellulose-based chiral stationary phase and determination of dexrabeprazole |
|
| Shuchi Dixit,Rituraj Dubey,Ravi Bhushan | | Biomedical Chromatography. 2013; : n/a | | [Pubmed] | [DOI] | | | 6 |
The chiral bioconversion and preclinical pharmacokinetic analysis of (R)-(+)-rabeprazole in beagle dogs by HPLC and HPLC-MS/MS |
|
| Yan-hui Gao,Jia-xing Xu,Zhong-xue Su,Li Song,Hong-xiang Lou | | Biomedical Chromatography. 2013; 27(11): 1380 | | [Pubmed] | [DOI] | | | 7 |
Antiulcer activity ofMuntingia calaburaleaves involves the modulation of endogenous nitric oxide and nonprotein sulfhydryl compounds |
|
| Tavamani Balan,Mohd. Hijaz Mohd. Sani,Velan Suppaiah,Norhafizah Mohtarrudin,Zarizal Suhaili,Zuraini Ahmad,Zainul Amiruddin Zakaria | | Pharmaceutical Biology. 2013; : 1 | | [Pubmed] | [DOI] | | | 8 |
Stability-indicating TLC-densitometric method for estimation of dexrabeprazole and domperidone in pharmaceutical dosage form |
|
| Chitlange, S.S., Mulla, A.I., Pawbake, G.R., Wankhede, S.B. | | Preparative Biochemistry and Biotechnology. 2010; 40(4): 337-346 | | [Pubmed] | | | 9 |
A postmarketing surveillance study of dexrabeprazole in the treatment of acid peptic disorders |
|
| Jain, S.C. | | Journal of the Indian Medical Association. 2009; 107(2): 111-113 | | [Pubmed] | | | 10 |
Is the required therapeutic effect always achieved by racemic switch of proton-pump inhibitors? |
|
| Zhou, Q., Yan, X.-F., Pan, W.-S., Zeng, S. | | World Journal of Gastroenterology. 2008; 14(16): 2617-2619 | | [Pubmed] | | | 11 |
Randomized, double-blind, comparative study of dexrabeprazole 10 mg versus rabeprazole 20 mg in the treatment of gastroesophageal reflux disease |
|
| Pai, V., Pai, N. | | World Journal of Gastroenterology. 2007; 13(30): 4100-4102 | | [Pubmed] | | | 12 |
Recent advances in chirally pure proton pump inhibitors |
|
| Pai, V., Pai, N. | | Journal of the Indian Medical Association. 2007; 105(8): 469-474 | | [Pubmed] | |
|
|
|
|
|
|
|
|
